Non-Hodgkin Lymphoma Patients' Survival Affected By Socioeconomic And Treatment Factors
Main Category: Lymphoma / Leukemia / MyelomaAlso Included In: Lymphology/Lymphedema; Seniors / Aging; Radiology / Nuclear Medicine
Article Date: 21 Oct 2008 - 4:00 PDT
| Patient / Public: | ![]() |
5 (1 votes) |
| Healthcare Prof: | ![]() |
Socioeconomic factors and the type of treatment received have an impact on a non-Hodgkin lymphoma (NHL) patient's risk of dying. That is the finding of a new study published in the December 1, 2008 issue of CANCER, a peer-reviewed journal of the American Cancer Society. The study reveals that poorer socioeconomic status increases a patient's risk of dying, while receiving chemotherapy reduces the risk.
NHL is a common type of cancer in the elderly. Its incidence has been increasing over the past several decades, and Caucasians have higher incidence and death rates related to the disease than patients in other ethnic groups. Newer treatments for NHL have become available in recent years; however, studies have not addressed ethnic disparities in survival as they relate to treatment, diagnosis, socioeconomic status, or other factors.
To investigate the issue, Dr. Xianglin Du of the University of Texas School of Public Health in Houston and colleagues analyzed SEER (Surveillance, Epidemiology and End Results)-Medicare linked data for more than 13,000 patients diagnosed at age 65 or older between 1992 and 1999. The metropolitan areas of San Francisco/Oakland, Detroit, Atlanta, Seattle, Los Angeles County, San Jose/Monterey, and the states of Connecticut, Iowa, New Mexico, Utah, and Hawaii were included in this study.
Dr. Du and his team analyzed data related to survival, socioeconomic status, treatment (chemotherapy or radiation), tumor factors (stage and type of NHL), the presence of other diseases or conditions, and other characteristics such as age, race, marital status, and geographic area.
The investigators found that receiving chemotherapy was associated with prolonged survival in patients with NHL and that elderly Caucasian patients with NHL were more likely to receive chemotherapy (52.4 percent) compared with African-Americans (43.2 percent). Also, poor socioeconomic status was significantly associated with increased risk of mortality, and there were a larger proportion of African-American patients living in poor communities compared with other ethnicities. No significant differences in the risk of death were seen between African-Americans and Caucasians after controlling for factors such as treatment and socioeconomic status.
###
Article: "Ethnic variations in diagnosis, treatment, socioeconomic status and survival in a large population-based cohort of elderly patients with Non-Hodgkin's Lymphoma." Michael Wang, Keith D. Burau, Shenying Fang, Harry Wang, and Xianglin L. Du. CANCER; Published Online: October 20, 2008 (DOI: 10.1102/cncr.23914); Print Issue Date: December 1, 2008.
Source: David Sampson
American Cancer Society
Visit our lymphoma / leukemia / myeloma section for the latest news on this subject.
MLA
15 Feb. 2012. <http://www.medicalnewstoday.com/releases/126178.php>
APA
http://www.medicalnewstoday.com/releases/126178.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.




